Moreover, our gene/microRNA expression data from a large cohort of primary CN-AML patients provides insights into the biological changes associated with varying MAPKBP1 expression levels in CN-AML, and might help direct new therapeutic strategies for CN-AML patients. The gene discussed is MAPKBP1; the disease is cyclic hematopoiesis.